Repligen Corporation (RGEN) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID warning (65/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+253.1% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
Repligen Corporation (RGEN) surged +2.14% to $188.64 as options desks priced 58% call premium vs. 42% put protection around the $185 max-pain magnet. Accounting Warning: Paper earnings outpaced operating cash flow (+253.1% (NI vs OCF)) as receivables rose.
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 10.9% year on year to $209.3 million. The company’s full-year revenue guid
Repligen’s third quarter was marked by revenue and non-GAAP profit that exceeded Wall Street expectations, driving a positive market reaction. Management attributed this performance to robust organic growth in proteins a
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of
Repligen Corporation (NASDAQ:RGEN) ("Repligen"), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 1.00% Convertible Senior
Conestoga Micro Cap Composite reports 3Q26 performance highlights and portfolio adjustments. Review the latest leadership and laggard insights here.
Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. In 2026, Small Caps initially outperformed but faced challenges in the third qu
Wasatch Global Investors, an asset management company, released its “Small Cap Growth Strategy” Q3 2026 investor letter. The letter can be downloaded here. The Wasatch Small Cap Growth strategy declined in Q3 2026 but ou
RBC Capital analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the price target from $185 to $200.
Repligen (RGEN) just booked record third quarter revenue of US$209.31 million, raised full year sales guidance, and leaned on its BioLife acquisition, even as impairment driven losses kept headline earnings in the red. R
Repligen reported record Q3 2026 revenue of US$209.31 million and nine-month revenue of US$607.7 million, while posting net losses for both periods, including a US$41.24 million intangible asset impairment in the quarter
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -3.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RGEN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RGEN. Explore sector supply chains on /butterfly.
Why RGEN Stock surged +2.14% Today — RQD Quant Desk Flash. Accounting Warning: Paper earnings outpaced operating cash flow (+253.1% (NI vs OCF)) as receivables rose.